Search Results 1-10 of 26572 for Alirocumab

  1. Alirocumab (Subcutaneous Route) Description and Brand Names - Mayo Clinic

    Alirocumab injection is used together with a proper diet and other medicines (eg, ezetimibe, statin medicine) to treat patients with primary hyperlipidemia ( ...

  2. Alirocumab (Subcutaneous Route) Proper Use - Mayo Clinic

    This medicine is given as a shot under your skin, usually in the stomach, thighs, or upper arms. Alirocumab may sometimes be given at home to patients who do ...

  3. Alirocumab (Subcutaneous Route) Side Effects - Mayo Clinic

    Chest pain or tightness · difficulty with breathing or swallowing · fast heartbeat · fever · hives, itching, skin rash · hoarseness · irritation · joint pain, ...

  4. Alirocumab (Subcutaneous Route) Precautions - Mayo Clinic

    Serious allergic reactions (eg, angioedema, vasculitis) may occur while you are using this medicine. Tell your doctor right away if you have a rash, itching ...

  5. Alirocumab (Subcutaneous Route) Before Using - Mayo Clinic

    Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of alirocumab injection in the elderly.

  6. Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy - Mayo Clinic

    Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis ...

  7. centers-of-excellence

    Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density ...

  8. New and novel treatments for hyperlipidemia - Mayo Clinic

    One approach has been to target biochemical pathways that impact LDL receptor availability. The human monoclonal antibodies evolocumab and alirocumab work by ...

  9. Familial hypercholesterolemia - Diagnosis & treatment - Mayo Clinic

    These newer drugs — alirocumab (Praluent) and evolocumab (Repatha) — help the liver absorb more LDL cholesterol, which lowers the amount of cholesterol ...

  10. PCSK9 inhibition: A game changer in cholesterol management - Mayo Clinic

    Alirocumab (Praluent), 75-150 mg every two weeks; Evolocumab (Repatha), 140 mg every two weeks or 420 mg monthly. The drugs are approved for the following ...